Published today in Neuron, co-first authors Jiyuan Yang, PhD, and Xue Zhang, PhD, and co-corresponding authors Jiyang Yu, PhD, and Junmin Peng, PhD, developed a cell type-specific protein atlas of Alzheimer’s disease identifying over 3,000 proteins with altered levels across a range of cell types.
Alzheimer’s disease can affect almost the entire brain, but how different cell types are specifically affected is not fully understood. To address this gap, St. Jude Children’s Research Hospital scientists developed a cell type-specific protein atlas using brains from mouse models of Alzheimer’s disease. By combining and comparing multiple types of data, they identified over 3,000 proteins with altered levels across a range of cell types, 78% of which had not been captured before. A focused look at microglia, which express many Alzheimer’s disease risk genes, revealed that almost all the changes to this cell type were previously undetected. The approach also uncovered a potential intercellular communication network, where proteins made in one cell type are secreted and function in another cell type. The findings, published today in Neuron, provide much-needed cell type-specific context to the pathology of Alzheimer’s disease.
Single-cell RNA sequencing has revolutionized Alzheimer’s disease research, but it provides only a partial view of cellular activity. Proteomic profiling fills many gaps, but has largely been limited to bulk analysis, resulting in lost context. Now, by combining next-generation mass spectrometry methods with single-cell RNA sequencing and spatial omics, co-corresponding authors Junmin Peng, PhD, Departments of Structural Biology and Developmental Neurobiology and Jiyang Yu, PhD, Department of Computational Biology interim chair, obtained the needed cell type-specific information.
“This is the first cell-type-resolved proteomic analysis we are aware of in the Alzheimer’s disease field. When we compared our data to bulk datasets, we found that a large portion of the protein level changes we detected are new,” Peng said. “We also identified many potential disease drivers that can be targeted in future follow-up studies.”
Integrated approach identifies RNA-protein level mismatch
Using two Alzheimer’s disease mouse models, the team profiled over 13,000 proteins across multiple ages and cell types. This profiling allowed direct comparison with single-cell RNA sequencing data, identifying thousands of cell type-specific changes in proteins, pathways and intercellular signaling networks.
“Because our lab specializes in deep proteomics, we were able to generate exceptionally robust datasets. That depth allowed meaningful comparisons with RNA data,” said co-first author Xue Zhang, PhD, a postdoctoral researcher in Peng’s lab. “Without sufficient coverage, such integration and analysis would not be possible.”
“By obtaining high-resolution cell-type proteomics, we now have an additional layer of information, especially with matched samples analyzed using multiple methods and at different levels of resolution,” said Yu. “These technologies enable us to understand disease mechanisms more comprehensively and identify specific cellular interactions, for example between microglia and astrocytes.”
Of note, RNA-protein level comparisons revealed that proteins found in one cell type were expressed by, and secreted from, another cell type. This was the case for the protein pleiotrophin, for which high RNA levels were noted in astrocytes, but high protein levels were found in microglia.
“Because those proteins are secreted, this suggested an interesting form of intercellular communication,” explained Peng. “Gene regulation may occur in astrocytes, but after translation and secretion, the proteins function in microglia.”
The atlas and accompanying datasets, available at https://penglab.shinyapps.io/pannda, provide a valuable resource that will allow researchers to make the leap into single-cell analysis in Alzheimer’s disease samples. “True integration has to start with experimental design, not after the data are generated,” said co-first author Jiyuan Yang, PhD, a senior computational research scientist in Yu’s lab. “It also requires a clear understanding of how different types of data can complement and inform each other. We hope our study provides a useful blueprint for future multi-omics research.”
Authors and funding
The study’s other co-corresponding author is Zhexing Wen, Emory University. The study’s other co-first authors are Kaiwen Yu and Him Shrestha, St. Jude; and Ying Zhou, Emory University. The study’s other authors are Yun Jiao, Ju Wang, Ping-Chung Chen, Zhen Wang, Xiaokang Ren, Huan Sun, Jay Yarbro, Zhiping Wu, Kiara Harper, Liusheng He, Zuo-Fei Yuan, and Anthony High, St. Jude; Danting Liu, St. Jude and Tufts Medical Center; Jie Xu, Emory University; and Xusheng Wang, University of Tennessee Health Science Center.
The study was supported by the National Institutes of Health (RF1AG068581, R01AG092468, RF1AG064909 and U19AG069701) and the American Lebanese Syrian Associated Charities (ALSAC), the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood catastrophic diseases. From cancer to life-threatening blood disorders, neurological conditions, and infectious diseases, St. Jude is dedicated to advancing cures and means of prevention through groundbreaking research and compassionate care. Through global collaborations and innovative science, St. Jude is working to ensure that every child, everywhere, has the best chance at a healthy future. To learn more, visit stjude.org, read St. Jude Progress, a digital magazine, and follow St. Jude on social media at @stjuderesearch.